Journal
IMMUNOLOGY AND CELL BIOLOGY
Volume 95, Issue 7, Pages 577-583Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/icb.2017.22
Keywords
-
Categories
Funding
- National Health and Medical Research Council [GNT1067511]
- BLF Pump Priming Grant
- Juvenile Diabetes Research Foundation [4-2006-1025]
- Diabetes Research Foundation of Western Australia
Ask authors/readers for more resources
Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. It is typically associated with extensive and progressive fibrosis, and is fatal and has limited treatment options. Characteristically IPF patients display large lymphocyte aggregates composed of CD3(+) T cells and CD20(+) B cells within the lung tissue that are located near sites of active fibrosis. In addition, IPF patients can have autoantibodies to a range of host antigens, suggesting a breakdown in immunological tolerance. In this review, we examine the role of T and B cells in IPF pathogenesis and discuss how loss of self-tolerance to lung-specific proteins could exacerbate disease progression in IPF. We discuss what these results mean in terms of future prospects for immunotherapy of IPF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available